The role of liquid biopsy as a catalyst for sustained progress in precision oncology – Perspective of the young committee of the international society of liquid biopsy
Erick Figueiredo Saldanha(Princess Margaret Cancer Centre), Carolina Reduzzi(Cornell University), Surbhi Singhal(International Society of Nephrology), Eleonora Nicolò(Cornell University), Diego de Miguel‐Pérez(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Angelo Dipasquale(IRCCS Humanitas Research Hospital), Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Konstantinos Venetis(European Institute of Oncology), Ana Ortega-Franco(The Christie NHS Foundation Trust), George Adigbli(University of Oxford)
Cited by 11
Related Papers
Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy
|Breast Cancer Research|2019|182
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
|Scientific Reports|2020|118
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
|Annals of Oncology|2023|103
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
|ESMO Open|2023|101
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors
|American Society of Clinical Oncology Educational Book|2023|92